Crispr Therapeutics Ag Stock Story
| CRSP Stock | USD 55.65 0.76 1.35% |
Slightly above 60% of Crispr Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Crispr Therapeutics AG suggests that many traders are alarmed. Crispr Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Crispr Therapeutics AG. The current market sentiment, together with Crispr Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Crispr Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Crispr Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Crispr daily returns and investor perception about the current price of Crispr Therapeutics AG as well as its diversification or hedging effects on your existing portfolios.
Crispr |
Requested story not found. it has been either deleted or moved. View all stories for Crispr Therapeutics AG.
Crispr Therapeutics Latest Timeline
Crispr Therapeutics is listed for 55.65. About 69.0% of the company shares are held by institutions such as insurance companies. The book value of Crispr Therapeutics was currently reported as 23.52. The company recorded a loss per share of 1.94. Crispr Therapeutics had not issued any dividends in recent years. The entity had 333333:100 split on the 19th of July 2016.Check out Crispr Therapeutics Hype Analysis, Crispr Therapeutics Correlation and Crispr Therapeutics Performance. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Crispr Stock analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.94) | Revenue Per Share 4.686 | Quarterly Revenue Growth 33.5 K | Return On Assets (0.06) | Return On Equity (0.08) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.